SCHEMBL343287

SCHEMBL343287

O=[N+]([O-])c1ccc(Cl)cc1C(O)c1ccc(Cl)nc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
PDE7A Q13946 3/20 0.37
AHR P35869 1/20 0.36
KMT2A Q03164 2/20 0.36
POLB P06746 4/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
VCAM1 P19320 1/20 0.35
ALDH1A1 P00352 5/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5583389 0.79 MAPK1 (0.49) TSHRMAPK1PDE7AKMT2APOLB
SCHEMBL27382568 0.78 TSHR (0.42) TSHRMAPK1PDE7AKMT2APOLB
SCHEMBL15308430 0.76 GAA (0.38) KMT2AMAPTCYP3A4CYP2D6SLC6A2
SCHEMBL10628834 0.76 CHEK2 (0.40) TSHRKMT2ALMNAMAPTALDH1A1
SCHEMBL2616495 0.73 TSHR (0.42) TSHRMAPK1PDE7AKMT2APOLB
SCHEMBL2616488 0.73 KMT2A (0.51) TSHRMAPK1PDE7AKMT2APOLB
SCHEMBL15013647 0.73 TSHR (0.42) TSHRMAPK1PDE7AKMT2APOLB
SCHEMBL2616489 0.73 MAPK1 (0.39) TSHRMAPK1PDE7AKMT2APOLB
SCHEMBL3253882 0.72 TSHR (0.51) TSHRMAPK1PDE7APOLBLMNA
SCHEMBL3299158 0.71 KCNQ3 (0.41) TSHRMAPK1KMT2ASMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10364240-B2 Aryl sulfonamides ChemoCentryx. Inc. (US) 2019-07-30 US disclosed
US-9890148-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2018-02-13 US disclosed
US-20170369483-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2017-12-28 US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 US disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 US disclosed
EP-1798223-B2 Aryl sulfonamides CHEMOCENTRYX INC (US) 2014-07-30 EP disclosed
US-20130267492-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2013-10-10 US disclosed
US-20130267492-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2013-10-10 US disclosed
CN-101077867-B Bis-aryl sulfonamides CHEMOCENTRYX 2012-10-10 CN disclosed
US-8211896-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2012-07-03 US disclosed
EP-1798223-A2 Aryl sulfonamides ChemoCentryx Inc (US) 2007-06-20 EP disclosed
US-20060111351-A1 Aryl sulfonamides CHEMOCENTRYX, INC. 2006-05-25 US disclosed
CN-1711257-A Aryl sulfonamides CHEMOCENTRYX (US) 2005-12-21 CN disclosed
WO-2005112925-A1 ARYL SULFONAMIDES CHEMOCENTRYX (US) 2005-12-01 WO disclosed
US-6939885-B2 Aryl sulfonamides CHEMOCENTRYX (US) 2005-09-06 US disclosed
EP-1562940-A2 ARYL SULFONAMIDES ChemoCentryx Inc (US) 2005-08-17 EP disclosed
US-20050165067-A1 Aryl sulfonamides CHEMOCENTRYX 2005-07-28 US disclosed
US-20050137193-A1 Aryl sulfonamides CHEMOCENTREYX 2005-06-23 US disclosed
US-20040171654-A1 Aryl sulfonamides CHEMOCENTRYX, INC. 2004-09-02 US disclosed
WO-2004046092-A2 ARYL SULFONAMIDES CHEMOCENTRYX (US) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137193-A1 Aryl sulfonamides CCR9, CCR1, CCR2 TSHR 1005/4885MAPK1 2440/4885PDE7A 2403/4885
US-10364240-B2 Aryl sulfonamides CCR9, CCR1, CCR2 TSHR 1005/4885MAPK1 2440/4885PDE7A 2403/4885
US-20060111351-A1 Aryl sulfonamides CCR9, CCR1, CCR2 TSHR 1005/4885MAPK1 2440/4885PDE7A 2403/4885
US-20170369483-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 TSHR 1005/4885MAPK1 2440/4885PDE7A 2403/4885
US-20150080351-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 TSHR 1005/4885MAPK1 2440/4885PDE7A 2403/4885
US-20040171654-A1 Aryl sulfonamides CCR9, CCR1, CCR2 TSHR 1005/4885MAPK1 2440/4885PDE7A 2403/4885
US-20050165067-A1 Aryl sulfonamides CCR9, CCR1, CCR2 TSHR 1005/4885MAPK1 2440/4885PDE7A 2403/4885
US-20130267492-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 TSHR 1005/4885MAPK1 2440/4885PDE7A 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.